Aligos Therapeutics (ALGS) Net Margin (2021 - 2025)
Historic Net Margin for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to 4256.01%.
- Aligos Therapeutics' Net Margin fell 27152900.0% to 4256.01% in Q3 2025 from the same period last year, while for Sep 2025 it was 3296.3%, marking a year-over-year decrease of 17615400.0%. This contributed to the annual value of 3633.65% for FY2024, which is 26947000.0% down from last year.
- Latest data reveals that Aligos Therapeutics reported Net Margin of 4256.01% as of Q3 2025, which was down 27152900.0% from 1643.83% recorded in Q2 2025.
- In the past 5 years, Aligos Therapeutics' Net Margin registered a high of 13854.66% during Q1 2025, and its lowest value of 13556.11% during Q4 2024.
- Its 5-year average for Net Margin is 1875.8%, with a median of 1388.35% in 2023.
- As far as peak fluctuations go, Aligos Therapeutics' Net Margin tumbled by -121677500bps in 2024, and later skyrocketed by 188781500bps in 2025.
- Over the past 5 years, Aligos Therapeutics' Net Margin (Quarter) stood at 10276.29% in 2021, then skyrocketed by 94bps to 618.77% in 2022, then tumbled by -124bps to 1388.35% in 2023, then plummeted by -876bps to 13556.11% in 2024, then soared by 69bps to 4256.01% in 2025.
- Its last three reported values are 4256.01% in Q3 2025, 1643.83% for Q2 2025, and 13854.66% during Q1 2025.